Skip to Content

How does Venclexta work?

Answers (1)

Official Answer by Drugs.com 5 May 2016

Venclexta (venetoclax) was FDA-approved in April 2016.

Venclexta, by AbbVie, is an oral B-cell lymphoma-2 (BCL-2) inhibitor for chronic lymphocytic leukemia (CLL) with 17p deletion. The 17p deletion is a chromosomal abnormality detected with a FDA-approved diagnostic test. The CLL cancer cell growth is fed by the BCL-2 protein, but Venclexta inhibits this protein.

In one study, 106 patients took increasing doses of the Venclexta pill once a day for five weeks. Results showed that 80% of patients either saw improvement or their cancer fully disappear.

Common side effects included low red and white blood cell count, diarrhea, nausea, and respiratory (lung) infections.

Votes: +0
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What is the difference between Biktarvy and Descovy?

Posted 7 Mar 2018 1 answerFAQ by Drugs.com

What is the difference between Symdeko and Orkambi?

Posted 7 Mar 2018 1 answerFAQ by Drugs.com